Future directions in obesity pharmacotherapy.

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Obesity is a complex chronic disease with significant unmet treatment needs.
• Current anti-obesity medications offer benefits but lack the efficacy of bariatric surgery for hard endpoint outcomes.
• Advances in understanding body weight regulation reveal new therapeutic targets.

Purpose of the Study:

• To review the current landscape of anti-obesity medications.
• To discuss the potential of novel gut peptide analogues and combination therapies.
• To highlight the need for updated regulatory standards for obesity treatments.

Main Methods:

• Review of current clinical development of obesity pharmacotherapies.
• Analysis of the efficacy of GLP-1 receptor agonists and dual GLP-1/GIP agonists.
• Discussion of emerging drug targets and combination strategies.

Main Results:

• Semaglutide and tirzepatide represent advanced therapeutic options targeting gut peptide pathways.
• These novel agents demonstrate significant potential for obesity treatment.
• Existing regulatory requirements may not align with the efficacy of new obesity compounds.

Conclusions:

• Novel pharmacotherapies, including gut peptide analogues, are poised to advance obesity treatment.
• Combination therapies may be necessary to maximize efficacy for complex metabolic conditions.
• Evolving treatment paradigms necessitate a re-evaluation of regulatory standards and personalized guidelines.